Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study

P. Lescuyer | M. Imboden | A. Flahault | A. Azman | N. Rodondi | M. Puhan | A. Camerini | M. Bochud | A. Chiolero | I. Guessous | L. Corna | S. Stringhini | N. Noël | T. Radtke | A. Butty | J. Pasquier | S. Kriemler | A. Frei | E. Albanese | D. Keidel | R. Morese | K. Zens | Sara Levati | L. Crivelli | P. Bodenmann | V. von Wyl | Maddalena Fiordelli | M. Tonolla | M. Zaballa | A. Schmid | N. Pullen | D. Menges | H. Aschmann | M. Kaufmann | T. Ballouz | J. Villers | A. Wisniak | G. Piumatti | H. Baysson | A. Ulytė | S. Sabatini | O. Duperrex | D. Paris | V. D'Acremont | P. Rodondi | A. Loizeau | A. M. Annoni | N. Ortega | N. Troillet | Julia Vincentini | Géraldine Poulain | C. Kahlert | S. Cullati | D. Anker | C. Robert | C. Martinez | M. Fadda | A. Anagnostopoulos | E. Harju | A. Domenghino | É. Masserey | P. Kohler | P. Chocano-Bedoya | A. Epure | J. Magnin | E. Lorthe | R. Dumont | V. Richard | N. Schwab | A. Cusini | Marco Geigges | S. Pfister | A. Jeong | Rylana Wenger | Aude Richard | M. Rasi | N. Probst-Hensch | Prune Collombet | C. Wagner | M. Schüpbach | S. Gonseth Nusslé | S. Tancredi | Simone Kessler | S. Estoppey | Richard Dubos | A. Felappi | Erin A. West | L. Kaiser | C. Semaani | J. Fehr | J. Dupraz | Vincent Faivre | J. Thabard | R. Amati | C. Zuppinger | Sophie Vassaux | A. Steiner-Dubuis | Kleona Bezani | Gisela Michel | Alexandre Speierer | Giovanni Franscella | A. Blattmann | Luc Fornerod | I. Frank | Thomas Vermes | Antonio Amendola | Agathe Deschamps | Malik Egger | Natalie Engler | Marion Frangville | Irène Frank | Emilie Jendly | Caroline Pugin | V. Schlüter | Valentine Schneider | P. D’ippolito | Christine Krähenbühl | Clément Graindorge | Antoine Bal | Patrick Bleich | Natalie Francioli | Séverine Harnal | Khadija Samir | Stéphanie Testini | Nacira El Merjani | Francesco Pennacchio | Peter Buttaroni | Chantal Luedi | Melissa Witzig | Nicolai Mösli | Julien Lamour | J. Zozaya | L. Kaufmann | Moa Lina Haller | Chantal Lüdi | Antonio Alexia Daniela Anna Maria Hélène Andrew Antoine Ta Amendola Anagnostopoulos Anker Annoni Asc | Diana Sofia Da Costa Santos | Emna El-May | Lukas Erksam | Cristina Fragoso Corti | E. West | Jennifer Villers | Patricia Chocano-Bedoya | Laurie M. Corna

[1]  F. Jalali,et al.  Inequality in the distribution of Covid-19 vaccine: a systematic review , 2022, International Journal for Equity in Health.

[2]  N. Rodondi,et al.  Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas , 2022, BMC Medicine.

[3]  V. von Wyl,et al.  Differences in COVID-19 vaccination uptake in the first 12 months of vaccine availability in Switzerland - a prospective cohort study. , 2022, Swiss medical weekly.

[4]  C. Alpuche-Aranda,et al.  Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico , 2022, Nature communications.

[5]  C. Kaplan,et al.  Relationship between mask wearing, testing, and vaccine willingness among Los Angeles County adults during the peak of the COVID-19 pandemic , 2021, Translational behavioral medicine.

[6]  A. Rezapour,et al.  Effectiveness of non-pharmaceutical public health interventions against COVID-19: A systematic review and meta-analysis , 2021, PloS one.

[7]  Z. Ademi,et al.  Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis , 2021, BMJ.

[8]  D. Mouly,et al.  Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study , 2021, BMJ Open.

[9]  J. Singleton,et al.  Racial and Ethnic Disparities in COVID-19 Vaccination Coverage: The Contribution of Socioeconomic and Demographic Factors , 2021, American Journal of Preventive Medicine.

[10]  A. Azman,et al.  Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  Neeti Zaman Bintee,et al.  The Impact of Community Masking on COVID-19: A Cluster-Randomized Trial in Bangladesh , 2021 .

[12]  A. Chiolero,et al.  Elimination of covid-19: beware of surveillance bias , 2021, BMJ.

[13]  P. Hotez,et al.  Update on SARS-CoV-2 seroprevalence: regional and worldwide , 2021, Clinical Microbiology and Infection.

[14]  A. Galvani,et al.  Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis , 2021, Proceedings of the National Academy of Sciences.

[15]  G. Severi,et al.  Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study , 2021, International journal of epidemiology.

[16]  John P. Moore,et al.  Predictors of Nonseroconversion after SARS-CoV-2 Infection , 2021, Emerging infectious diseases.

[17]  S. Cauchemez,et al.  Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study , 2021, The Lancet Regional Health - Europe.

[18]  Belayneh Mengist,et al.  Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis , 2021, PloS one.

[19]  M. Nussenzweig,et al.  Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.

[20]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study , 2020, medRxiv.

[21]  M. van Boven,et al.  Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave , 2020, Journal of Epidemiology & Community Health.

[22]  D. Clifton,et al.  Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis , 2020, medRxiv.

[23]  P. Galanis,et al.  Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis , 2020, Journal of Hospital Infection.

[24]  G. Pantaleo,et al.  Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies , 2020, Journal of Virology.

[25]  M. Imboden,et al.  Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland , 2020, International Journal of Public Health.

[26]  P. Glasziou,et al.  Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review , 2020, PloS one.

[27]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.

[28]  Joshua M Sharfstein,et al.  Diagnostic Testing for the Novel Coronavirus. , 2020, JAMA.

[29]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[30]  F. Reinach,et al.  Population-based age-stratified seroepidemiological investigation , 2020 .

[31]  Doojin Song.  Università della Svizzera Italiana , 2004 .

[32]  M. Reavey,et al.  University of Lausanne , 1937, Nature.